Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms

• Status: Completed
• Trial end date: 2021-05-11
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There will be two cohorts of participants:

• Cohort 1: Participants with relapsed or refractory extranodal NK/T cell lymphoma (nasal or non-nasal type)

• Cohort 2: other mature T-cell neoplasms (limited to the following histologies:

peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma, or anaplastic large-cell lymphoma)

• Cohort 3: cutaneous T-cell lymphoma (limited to mycosis fungoides and Sèzary syndrome)

Up to 70 participants will be enrolled into cohort 1, up to 50 participants into cohort 2, and up to 10 participants into cohort 3 for a total sample size of up to 130 participants.

The primary efficacy endpoint is overall response rate (ORR) determined by investigator assessment. Disease response for the primary endpoint for cohorts 1 and 2 will be assessed per the Lugano criteria with LYRIC modification for immunomodulatory therapy Disease response for the primary endpoint for cohort 3 will be assessed per the International Society for Cutaneous Lymphoma (ISCL)/European Organization for Research and Treatment of Cancer (EORTC) guidelines for immunomodulatory therapy BGB-A317 will be administered intravenously as a 200 mg infusion every 3 weeks (Each cycle consists of 21 days). Study procedures will occur over a Screening phase (up to 35 days); Treatment phase (until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first); Safety Follow-up phase (up to 90 days following last study treatment for all adverse events (AEs) and serious adverse events (SAEs)); Survival follow-up phase (duration varying by participant).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BeiGene

Criteria

Key Inclusion Criteria

• Confirmed diagnosis of relapsed or refractory extranodal NK/T-cell lymphoma (nasal or non-nasal type, peripheral T-cell lymphoma - not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, or Sezary syndrome

• Age 18 years or older

• Relapsed or refractory to at least 1 prior systemic therapy

• Measurable disease by CT/magnetic resonance imaging (MRI) for participants in Cohort 1 and 2

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

• Life expectancy ≥ 6 months

• Adequate respiratory function

• Adequate bone marrow function

• Adequate renal and hepatic function

Key Exclusion Criteria

• Known central nervous system (CNS) involvement by lymphoma

• Previously received immune checkpoint therapy

• Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 or lower prostate cancer

• Active autoimmune disease or history of autoimmune diseases that may relapse with some exceptions

• Severe or debilitating pulmonary disease

• Clinically significant cardiovascular disease

• Active fungal, bacterial, and/or viral infection requiring systemic therapy

• Known infection with HIV or active viral hepatitis B or C infection

• Major surgery within 4 weeks of the first dose of study drug

• Pregnant or lactating women

• Vaccination with a live vaccine within 35 days prior to the first dose of study drug

• Hypersensitivity to tislelizumab

• Concurrent participation in another therapeutic clinical trial

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.